Literature DB >> 1984982

Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population.

J L Sebastian1, W P McKinney, J Kaufman, M J Young.   

Abstract

To determine the frequency of ACE inhibitor cough in an outpatient medical clinic population, a cross-sectional epidemiologic survey using mailed questionnaires was done. Patients were randomly selected from a computerized hospital pharmacy data base. The overall prevalence of cough was 19 percent in the ACE inhibitor groups compared with 9 percent in the hydrochlorothiazide-treated group. The observed odds ratio for cough among ACE inhibitor users was 2.3 (95 percent CI, 1.02 to 5.00). This study is the first systematic investigation of frequency and characteristics of ACE inhibitor cough that includes a control group. Our results suggest that cough may more frequently accompany treatment with ACE inhibitors than has been previously reported. We recommend that physicians specifically inquire about cough in patients taking an ACE inhibitor. Recognition of this side effect may prevent unnecessary testing and treatment of patients receiving ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984982     DOI: 10.1378/chest.99.1.36

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  A double-blind randomised comparison of perindopril and ketanserin in the treatment of hypertension in elderly diabetic patients.

Authors:  J Woo; K S Woo; K H Or; C S Cockram; M G Nicholls
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

Review 2.  ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.

Authors:  A Overlack
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 3.  Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.

Authors:  Krishna Sriram; Rohit Loomba; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-17       Impact factor: 11.205

4.  A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pithed rat and guinea-pig.

Authors:  M Rechtman; H Majewski
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

5.  Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough.

Authors:  Takeshi Morimoto; Tejal K Gandhi; Julie M Fiskio; Andrew C Seger; Joseph W So; E Francis Cook; Tsuguya Fukui; David W Bates
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 6.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 7.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

8.  Effect of dose adjustment on enalapril-induced cough and the response to inhaled capsaicin.

Authors:  W W Yeo; K S Higgins; G Foster; P R Jackson; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 9.  Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.

Authors:  S Noble; E M Sorkin
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

10.  High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.

Authors:  K S Woo; M G Nicholls
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.